BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERSTASK ORDER TITLE: VACCINES AGAINS
基本标题:预防临床前药物开发计划:临床前疗效和中间终点 BIOMAKERSTASK 订单标题:再次疫苗
基本信息
- 批准号:10651935
- 负责人:
- 金额:$ 61.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-06-15 至 2023-12-14
- 项目状态:已结题
- 来源:
- 关键词:APC geneAdultAdverse effectsAdvisory CommitteesAfrican AmericanAgeAmericanAnaerobic BacteriaAnimalsAntibioticsAntigensApcMin/+ miceBacillusBacteriaBacteroides fragilisBindingBiologicalCOVID-19Cancer EtiologyCell physiologyCell-Mediated CytolysisChemopreventive AgentChildClinicalCodon NucleotidesColitisColonoscopyColorectalColorectal AdenomaColorectal CancerColorectal NeoplasmsColorectal PolypContainmentDNADataDental PlaqueDevelopmentDiagnosisDiseaseDistantDistant MetastasisDysplasiaEncapsulatedEnhancersEpitopesFamilial Adenomatous Polyposis SyndromeFamily history ofFecesFusobacteriaFusobacterium nucleatumGeneticGerm-Line MutationGoalsGram-Negative BacteriaHelicobacter pyloriHepatitis B VirusHereditary Nonpolyposis Colorectal NeoplasmsHumanHuman Papilloma Virus VaccineITIMImmuneImmune SeraImmunityImmunoglobulinsImmunosuppressionIncidenceIndividualInfectionInfection preventionInfectious AgentInflammatory Bowel DiseasesInheritedInnate Immune ResponseInterventionLeadLesionMalignant NeoplasmsMalignant neoplasm of cervix uteriMalignant neoplasm of gastrointestinal tractMeasuresMediatingMembraneMessenger RNAMethodologyMicrosatellite InstabilityMismatch RepairMismatch Repair DeficiencyModelingModificationMorbidity - disease rateNatural Killer CellsNeoplasm MetastasisNon-Insulin-Dependent Diabetes MellitusNonsense MutationObesityOncogenicOperative Surgical ProceduresOralOrganPatientsPhasePopulationPreclinical Drug DevelopmentPrevalencePreventivePreventive measurePreventive servicePreventive vaccinePrimary carcinoma of the liver cellsProgram DevelopmentProteinsProteomicsPseudouridineRNARNA vaccineRaceRecommendationRecording of previous eventsRegimenRegulatory T-LymphocyteReporterResistanceRiskRisk FactorsRoleSmall Intestinal NeoplasmSurvival RateSyndromeSystemT-LymphocyteTimeTissuesTumor EscapeUnited StatesUnited States National Library of MedicineUpdateVaccinationVaccine AntigenVaccinesVesicleVirulence FactorsWild Type Mouseadenomaagedbasebiomaterial compatibilitycancer riskcigarette smokingcolorectal cancer riskcolorectal cancer screeningcoronavirus diseasedesigndraining lymph nodeeffector T cellefficacy testinggene repairglycerophosphodiester phosphodiesteraseimmunogenicimmunogenicityimprovedin vivoinfection ratelipid nanoparticlemalignant breast neoplasmmalignant stomach neoplasmmicrobiotamortalitymouse modelmutation carrierneoplastic cellpathogenpreclinical efficacypremalignantpreventprophylacticreceptorscale upscreeningtumortumor growthtumor microenvironmenttumorigenesistumorigenicvaccine platformvaccinology
项目摘要
Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality worldwide. In the Unites States, an estimated 151,300 Americans will be diagnosed with CRC and over 52,580 are expected to die from the disease in 2022 alone (https://seer.cancer.gov/statfacts/html/colorect.html). While the five-year survival rate for localized CRC is excellent at 90%, more than half of new CRC cases have the disease spread to regional lymph nodes and/or distant organs at the time of diagnosis. CRC with distant metastasis has a dismal five-year survival rate of 14.7%. These data clearly indicate that CRC-related mortality can be significantly improved if the disease is detected early and proper interventions could be deployed. Because CRC typically originates from precancerous colorectal polyps, routine colonoscopy screening provides an excellent opportunity to detect precursor or early lesions and reduce CRC-related morbidity and mortality. Indeed, the US Preventive Services Task Force recently updated its recommendation on CRC screening, noting the evidence that the screening in average-risk asymptomatic adults aged 50 to 75 years is of substantial benefit.
Risk factors for CRC include age (>50), race (African American), obesity, cigarette smoking, type II diabetes, history of inflammatory bowel diseases, family history of colorectal polyps or CRC, and inherited genetic syndromes known to increase the CRC risks, such as familial adenomatous polyposis (FAP) and Lynch syndrome. FAP and Lynch syndrome are caused by germline mutations in the APC gene and DNA mismatch repair genes, respectively. The management of individuals with hereditary gastrointestinal cancer syndromes requires additional measures beyond what is recommended for the average-risk population to minimize the overall risk of cancer-associated morbidity and mortality. Management options for the confirmed mutation carriers include multiple aggressive screening, chemopreventive strategies, and prophylactic surgery. However, these interventions are associated with various degrees of adverse effects. Safer and more effective preventive measures are urgently needed for the individuals with FAP, Lynch syndrome, and other hereditary gastrointestinal cancer syndromes.
Fusobacteria are common human oral gram-negative anaerobic microflora isolated from dental plaque and gum diseases, but rarely detectable in the colorectum of healthy individuals. In recent years, the enrichment of a specific pathotype, Fusobacterium nucleatum (Fn), has been demonstrated in the colonic tissues and stools from patients with colorectal adenomas and CRC. Clinical evidence suggests that the prevalence of Fn progressively increases from dysplasia, adenomas to CRC and the higher amount of Fn is significantly associated with CRC with high microsatellite instability, which is caused by DNA MMR deficiencies as seen in Lynch syndrome-associated CRC. The potential association of Fn with CRC tumorigenesis has been examined in a mouse model of FAP. ApcMin/+ mice, which carry a nonsense mutation at codon 850 of the Apc gene, had a significantly accelerated onset and increased multiplicity of both small intestinal and colorectal tumors after oral inoculation of Fn. These data strongly suggested the tumor-promoting role of Fn in ApcMin/+ mice. Interestingly, Fn did not induce colitis in these animals, in contrast to enterotoxigenic Bacteroides fragilis, which has been shown to cause colitis and accelerate tumorigenesis in ApcMin/+ mice. It has also been demonstrated that Fn promotes CRC, breast, and cervical cancer metastasis and can metastasizes with tumor cells.
Although how Fn contributes to CRC tumorigenesis has yet to be fully elucidated, emerging evidence points to its virulence factors, such as FadA and Fap2, as potential enhancers of CRC tumorigenesis and progression. The Fap2 has been shown to bind to human T-cell immunoglobulin ITIM domain (TIGIT), an immunoglobulin superfamily receptor known to function as an immune co-inhibitory molecule. Fap2-binding to TIGIT on NK and other T cells protects tumor cells from NK cell-mediated cytotoxicity and blocks effector T cell functions in the tumor microenvironment. TIGIT has also been shown to promote Treg function. Taken together, Fn may exert tumor promoting effects not only by promoting CRC tumor growth, but also by exploiting the immune-suppressive function of TIGIT via its virulence factor protein and contributing to tumor immune evasion mechanisms.
Cancers caused by infectious agents are theoretically preventable, if one can prevent the infection, eradicate oncogenic pathogens before tumor development, or suppress the functions of oncogenic molecules. Prophylactic vaccines for human papillomavirus and hepatitis B virus have been associated with significant reductions in infection rates, which are expected to result in the dramatic decrease in the incidence of cervical cancers and hepatocellular carcinoma, respectively. Compared to the prevention of infection, the eradication of oncogenic infectious agents already colonized in the host is in general highly challenging, if not impossible. For example, the well-established eradication regimens for Helicobacter pylori, which increases the risk of noncardia gastric cancers, do not eradicate the bacteria in all cases. Rather, emerging resistance to multiple antibiotics appears to be contributing to the recent decline in the eradication rate.
Alternatively, the host immune defense system may be fortified by pathogen-targeted vaccines, if they can boost anti-pathogen immunity and lead to the containment of infection or suppression of pathogen-mediated tumorigenic functions. Fn is a gram-negative anaerobic bacillus, and can be isolated from 60-70% of children aged 5-7 years. As with other gram-negative bacteria, Fn produces outer membrane vesicles (OMVs), which contain much of the biological content of the Fn, but without replicative capacity and some of the soluble proteins found in OMVs may elicit anti-Fn immunity. As part of the PREVENT project to develop Fn OMV based anti-Fn vaccine (https://reporter.nih.gov/project-details/9358850), the proteomic characterization of Fn OMV led to the identification of putative immunogenic components, some of which may be useful as anti-Fn vaccine antigens.
Lipid nanoparticle (LNP)-encapsulated mRNA vaccines against COVID-19 revolutionized the implementation of mRNA-based vaccinology. In addition to modifications of mRNA such as with pseudouridine incorporation to reduce innate immune responses and mRNA purification methodologies to remove contaminants, the development of biocompatible LNPs significantly boosted the advancement of COVID and other mRNA-based vaccines. LNP-RNA vaccine platform offers several advantages over conventional protein-based vaccination, including a rapid development, refined adjustment of antigenic epitopes, easier scale-up and timely deployment. The the current study aims to develop and evaluate the immunogenicity of soluble protein-based and LNP-RNA-based Fn vaccines and to determine anti-Fn activity and immunopreventive efficacy of Fn-associated CRC, using mouse models of FAP and Lynch syndrome.
结直肠癌(CRC)是全球癌症相关死亡的主要原因之一。在美国,估计有151,300名美国人将被诊断患有CRC,预计仅在2022年就将有超过52,580人死于该疾病(https://seer.cancer.gov/statfacts/html/colorect.html)。虽然局部结直肠癌的5年生存率为90%,但超过一半的新发结直肠癌病例在诊断时已经扩散到区域淋巴结和/或远处器官。伴有远处转移的结直肠癌的5年生存率只有14.7%。这些数据清楚地表明,如果早期发现这种疾病并采取适当的干预措施,与crc相关的死亡率可以显著提高。由于结直肠癌通常起源于癌前结肠息肉,常规结肠镜筛查提供了一个很好的机会来发现前体或早期病变,并降低结直肠癌相关的发病率和死亡率。事实上,美国预防服务工作组最近更新了其关于CRC筛查的建议,并指出有证据表明,在50至75岁的平均风险无症状成年人中进行筛查具有实质性的益处。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARGIE CLAPPER其他文献
MARGIE CLAPPER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARGIE CLAPPER', 18)}}的其他基金
TASK ORDER TITLE: MICROBIAL METABOLITE MIMICRY, A NANO-DRUG FOR COLON CANCER PREVENTIONPREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFF
任务单标题:微生物代谢物拟态,一种预防结肠癌的纳米药物预防临床前药物开发计划:临床前 EFF
- 批准号:
10706658 - 财政年份:2022
- 资助金额:
$ 61.42万 - 项目类别:
TASK ORDER TITLE: NEXT GENERATION GP130/IL-6/STAT3 INHIBITORS FOR THE PREVENTION OF COLITIS-ASSOCIATED COLORECTAL CANCER
任务单标题:用于预防结肠炎相关结直肠癌的下一代 GP130/IL-6/STAT3 抑制剂
- 批准号:
10627413 - 财政年份:2022
- 资助金额:
$ 61.42万 - 项目类别:
TASK ORDER: PREVENTING LUNG CANCER BY TARGETING ACTIVATED STAT3
任务顺序:通过针对激活的 STAT3 来预防肺癌
- 批准号:
10269147 - 财政年份:2020
- 资助金额:
$ 61.42万 - 项目类别:
HHSN2612012000151/HHSN2610006Base Contract Title: Preclinical Efficacy and Intermediate Biomarkers. Task Order Title: Modulation of miRNA Expression in Blood or Other Biological Fluids Compared wi
HHSN2612012000151/HHSN2610006基本合同标题:临床前功效和中间生物标志物。
- 批准号:
8947461 - 财政年份:2014
- 资助金额:
$ 61.42万 - 项目类别:
PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKER ASSAYS
临床前疗效和中间生物标志物测定
- 批准号:
7543325 - 财政年份:2004
- 资助金额:
$ 61.42万 - 项目类别:
PRECLINICAL EVALUATION OF INTERMEDIATE ENDPOINTS AND
中间终点的临床前评估和
- 批准号:
3617865 - 财政年份:1992
- 资助金额:
$ 61.42万 - 项目类别:
PRECLINICAL EVALUATION OF INTERMEDIATE ENDPOINTS AND
中间终点的临床前评估和
- 批准号:
3617866 - 财政年份:1992
- 资助金额:
$ 61.42万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 61.42万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 61.42万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 61.42万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 61.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 61.42万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 61.42万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 61.42万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 61.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 61.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 61.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)